These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12966674)

  • 21. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors.
    Tanvetyanon T; Hines E
    Cancer; 2005 Apr; 103(8):1756-7; author reply 1757-8. PubMed ID: 15751014
    [No Abstract]   [Full Text] [Related]  

  • 22. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronic acid: a new advance in managing skeletal events in prostate cancer.
    Kirby RS
    BJU Int; 2003 Apr; 91(6):464-5. PubMed ID: 12656892
    [No Abstract]   [Full Text] [Related]  

  • 24. Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.
    Terpos E
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S1-2. PubMed ID: 21353175
    [No Abstract]   [Full Text] [Related]  

  • 25. Home infusions of biphosphonate in cancer patients: a prospective study.
    Italiano A; Ciais C; Chamorey E; Marcy PY; Largillier R; Ferrero JM; Thyss A
    J Chemother; 2006 Apr; 18(2):217-20. PubMed ID: 16736892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
    Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of zoledronic acid in the treatment of breast cancer].
    Chen J; Liu ZY; Zhao LJ
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
    [No Abstract]   [Full Text] [Related]  

  • 29. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
    Pouessel D; Culine S
    Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer: targeted therapy for prostate cancer metastases to bone.
    Coleman R
    Nat Rev Urol; 2011 May; 8(6):296-8. PubMed ID: 21587226
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
    Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
    Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
    Joensuu TK
    Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases.
    Song Z; Zhang Y
    Med Oncol; 2014 Apr; 31(4):898. PubMed ID: 24573639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrolyte abnormalities with zoledronic acid therapy.
    Sorscher SM
    Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
    Yaman E; Benekli M; Coskun U; Ozturk B; Kaya AO; Yildiz R; Buyukberber S
    Ann Oncol; 2008 Feb; 19(2):397-8; author reply 398. PubMed ID: 18260185
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Berruti A; Tucci M; Terrone C; Scarpa RM; Angeli A; Dogliotti L
    J Natl Cancer Inst; 2003 Feb; 95(4):332-3; author reply 333-4. PubMed ID: 12591993
    [No Abstract]   [Full Text] [Related]  

  • 37. [Bisphosphonates in bone metastases. Fewer fractures, less pain].
    MMW Fortschr Med; 2002 Sep; 144(39):53. PubMed ID: 12422697
    [No Abstract]   [Full Text] [Related]  

  • 38. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
    Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long interval zoledronic acid use in bone metastases.
    Das M
    Lancet Oncol; 2017 Feb; 18(2):e72. PubMed ID: 28089632
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.